Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Bukwang Pharmaceutical Co Ltd (Bukwang) is a pharmaceutical company that manufactures and sells prescription drugs, over-the-counter drugs, nutraceuticals, and personal care products. Its pipeline products include Lurasidone for major depressive disorder, BUK-001 for Parkinson's disease, CP-012 for Morning OFF in Parkinson's disease, CP-102 for Canavan disease, other Contera rare-disease programs for rare diseases, and JaguAhR for AhR-mediated disorders. Its prescription drug portfolio includes products for central nervous system disorders, endocrinology, diabetic peripheral neuropathy, gastroenterology, oncology, respiratory conditions, cardiology, dermatology, urology, pain management, and iron-deficiency anemia. It operates in Denmark, South Korea, Singapore, and Israel. Bukwang Pharmaceutical is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
7, Sangdo-Ro, Dongjak-Gu, Seoul, 06955
Website
www.bukwang.co.kr
Telephone
82 2 8288114
No of Employees
648
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
003000 (KRX)
Revenue (2024)
$141.3M
25.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
575.4%
(2024 vs 2023)
Market Cap*
$302.8M
Net Profit Margin (2024)
XYZ
479.4%
(2024 vs 2023)
* As of and is in US$
Bukwang Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription | SirinMED |
| Central Nervous System | FEskimo |
| Endocrinology | Tavex |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
Competitor Comparison
| Key Parameters | Bukwang Pharmaceutical Co Ltd | Chong Kun Dang Pharmaceutical Corp. | Daewoong Pharmaceutical Co Ltd | Hanmi Pharmaceuticals Co Ltd | Ildong Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Seoul | Hwaseong | Hwaseong | Seoul |
| State/Province | Seoul | Seoul | - | Seoul | - |
| No. of Employees | 648 | 1,904 | 1,742 | 2,319 | 1,433 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jae Young Lee | Chief Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer